← Back to Screener
Replimune Group, Inc. (REPL)
Price$2.07
Favorite Metrics
Price vs S&P 500 (26W)-61.49%
Price vs S&P 500 (4W)-78.48%
Market Capitalization$170.93M
All Metrics
Book Value / Share (Quarterly)$2.64
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.55
Price vs S&P 500 (YTD)-82.63%
EPS (TTM)$-3.44
10-Day Avg Trading Volume14.69M
EPS Excl Extra (TTM)$-3.44
EPS (Annual)$-3.07
ROI (Annual)-50.70%
Cash / Share (Quarterly)$3.38
ROA (Last FY)-44.85%
EBITD / Share (TTM)$-3.51
ROE (5Y Avg)-38.68%
Cash Flow / Share (Annual)$-2.58
P/B Ratio0.81x
P/B Ratio (Quarterly)3.62x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-63.50x
ROA (TTM)-72.22%
EPS Incl Extra (Annual)$-3.07
Current Ratio (Annual)7.95x
Quick Ratio (Quarterly)5.43x
3-Month Avg Trading Volume2.94M
52-Week Price Return-74.11%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.88
52-Week High$13.24
EPS Excl Extra (Annual)$-3.07
CapEx CAGR (5Y)0.45%
Tangible BV CAGR (5Y)56.96%
26-Week Price Return-54.61%
Quick Ratio (Annual)7.82x
13-Week Price Return-71.64%
Total Debt / Equity (Annual)0.17x
Current Ratio (Quarterly)5.60x
Enterprise Value$120.593
Book Value / Share Growth (5Y)1.51%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.28
3-Month Return Std Dev166.00%
Net Income / Employee (TTM)$-1
ROE (Last FY)-59.47%
Net Interest Coverage (Annual)-83.16x
EPS Basic Excl Extra (Annual)$-3.07
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$-3.44
ROI (TTM)-83.10%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.80
Price vs S&P 500 (52W)-108.74%
Year-to-Date Return-78.70%
5-Day Price Return6.15%
EPS Normalized (Annual)$-3.07
ROA (5Y Avg)-31.31%
Month-to-Date Return-72.94%
Cash Flow / Share (TTM)$-3.02
EBITD / Share (Annual)$-3.20
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-34.00%
LT Debt / Equity (Quarterly)0.23x
EPS Basic Excl Extra (TTM)$-3.44
P/TBV (Quarterly)1.32x
P/B Ratio (Annual)1.81x
Book Value / Share (Annual)$5.39
Price vs S&P 500 (13W)-74.02%
Beta0.14x
Revenue / Share (TTM)$0.00
ROE (TTM)-102.69%
52-Week Low$1.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
REPLReplimune Group, Inc. | — | — | — | — | $2.07 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 11.09x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies for solid tumors using its proprietary RPx platform, which leverages an engineered HSV-1 virus to maximize immune activation against cancer. The company's pipeline includes three product candidates: RP1, RP2, and RP3. Replimune operates primarily in the United States with additional operations in the UK.